# Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment

> **NCT03926052** · PHASE3 · COMPLETED · sponsor: **Yale University** · enrollment: 61 (actual)

## Conditions studied

- Binge-Eating Disorder
- Obesity

## Interventions

- **DRUG:** Lisdexamfetamine Dimesylate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03926052
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-07
- **Primary completion:** 2024-11-18
- **Final completion:** 2024-11-18
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03926052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03926052, "Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT03926052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*